Abcam, ab272697, Anti-ICOS Ligand/ICOSL antibody [EPR23289-152] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ICOS Ligand/ICOSL antibody. Carrier free. Suitable for Flow Cyt and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23289-152,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab272697 is the carrier-free version of
ab233554
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ICOS Ligand also known as ICOSL B7-H2 and HK53 is a critical component in immune system function. This protein with a molecular mass of approximately 65 kDa is expressed on professional antigen-presenting cells such as dendritic cells macrophages and B cells. It plays a significant mechanical role in the immune response by engaging with its counter receptor the ICOS protein present on the surface of activated T cells. This interaction supports the regulation of T cell activity influencing proliferation and cytokine production.
Biological function summary
ICOSL contributes to the modulation of immune responses. By forming a complex with the active ICOS protein ICOSL is involved in the co-stimulation of T cells. This process is important for the development of T-cell-dependent immune responses and helps in promoting the survival and differentiation of T cells. Together the ICOS ligand and ICOS protein create a dynamic interaction that balances immune activation and tolerance which is essential for maintaining immune homeostasis.
Pathways
The ICOS-ICOSL interaction plays an important role in the T-cell receptor (TCR) signaling pathway. This pathway is fundamental for the activation of T cells and subsequent immune response. ICOSL also connects to the PI3K/Akt pathway where it impacts cell survival and proliferation. ICOS and the PI3K/Akt pathway work together to influence various aspects of immune regulation and adaptive immunity.
ICOSL has a notable impact on autoimmune diseases and cancer. Its function in immune modulation when dysregulated can contribute to autoimmune conditions such as systemic lupus erythematosus. In this context the abnormal activation of the ICOS protein may exaggerate immune responses leading to pathology. In cancer high expression of ICOSL can support tumor progression by affecting the immune surveillance capability. These associations reveal ICOSL’s role in balancing immune activation and inhibition which is important in the context of disease.